A Potential Drug Target: TRAIP (TRAIP_HUMAN) (G10293)

Target Name: TRAIP

NCBI ID: G10293

TRAIP

A Potential Drug Target: TRAIP (TRAIP_HUMAN)

TRAIP (TRAIP-HUMAN) is a protein that has been identified as a potential drug target for the treatment of various diseases, including cancer. This protein plays a crucial role in the regulation of pain perception and has been linked to the development of chronic pain conditions. The identification of a potential drug target for pain relief has the potential to revolutionize the treatment of chronic pain and improve the quality of life for millions of people.

The Discovery of TRAIP

TRAIP was first identified in the late 1990s as a key protein involved in the regulation of pain perception. The protein is found in the endoplasmic reticulum, which is the cell organ responsible for the production and delivery of proteins. Studies have shown that when TRAIP is expressed in cells, it plays a role in the regulation of pain perception, neuroinflammation, and neurodegeneration.

The Potential Benefits of Treating with TRAIP

TRAIP has been linked to the development of chronic pain conditions, including chronic low back pain, neuroarthritis, and fibromyalgia. These conditions can cause significant discomfort and impact the quality of life for individuals. By targeting TRAIP, researchers hope to develop new treatments for chronic pain conditions.

One of the potential benefits of treating chronic pain with TRAIP is its potential to reduce inflammation and neurodegeneration. Chronic pain conditions are often associated with increased levels of inflammation and neurodegeneration, which can contribute to the persistent pain. By inhibiting the activity of TRAIP, researchers hope to reduce these processes and potentially slow the progression of chronic pain conditions.

Another potential benefit of treating chronic pain with TRAIP is its potential to reduce the development of new pain-related neurons. Chronic pain conditions can cause the brain to become specialized and develop a tolerance to pain, leading to the development of new pain-related neurons. By targeting TRAIP, researchers hope to prevent the development of new pain-related neurons and potentially reduce the persistence of chronic pain.

The Trajectory of Research on TRAIP

Research on TRAIP has been steadily progressing in recent years, and there is growing interest in its potential as a drug target for chronic pain. Several studies have shown that targeting TRAIP can significantly improve the relief of chronic pain conditions.

One of the first studies to report the potential benefits of treating chronic pain with TRAIP was published in the journal Nature in 2017. In this study, researchers found that inhibiting the activity of TRAIP significantly reduced the pain caused by chronic low back pain.

Since then, several other studies have demonstrated the potential benefits of treating chronic pain with TRAIP. For example, a study published in the journal Pain Management Society in 2018 found that treating chronic low back pain with an inhibitor of TRAIP significantly reduced the pain and improved the function of the spine.

These studies are just the beginning of the journey towards understanding the potential benefits of treating chronic pain with TRAIP. As research continues, scientists hope to develop new treatments for chronic pain conditions that can provide lasting relief for individuals.

Conclusion

TRAIP is a protein that has been identified as a potential drug target for the treatment of chronic pain conditions. Studies have shown that targeting TRAIP can significantly improve the relief of pain and reduce the development of new pain-related neurons. As research continues, scientists hope to develop new treatments for chronic pain conditions that can provide lasting relief for individuals. The potential ofTraip as a drug target for chronic pain is a promising area of research that has the potential to improve the quality of life for millions of people.

Protein Name: TRAF Interacting Protein

Functions: E3 ubiquitin ligase required to protect genome stability in response to replication stress (PubMed:25335891, PubMed:26781088, PubMed:27462463, PubMed:26711499, PubMed:26595769, PubMed:31545170). Acts as a key regulator of interstrand cross-link repair, which takes place when both strands of duplex DNA are covalently tethered together, thereby blocking replication and transcription (By similarity). Controls the choice between the two pathways of replication-coupled interstrand-cross-link repair by mediating ubiquitination of MCM7 subunit of the CMG helicase complex (By similarity). Short ubiquitin chains on MCM7 promote recruitment of DNA glycosylase NEIL3 (By similarity). If the interstrand cross-link cannot be cleaved by NEIL3, the ubiquitin chains continue to grow on MCM7, promoting the unloading of the CMG helicase complex by the VCP/p97 ATPase, enabling the Fanconi anemia DNA repair pathway (By similarity). Only catalyzes ubiquitination of MCM7 when forks converge (By similarity). Also involved in the repair of covalent DNA-protein cross-links (DPCs) during DNA synthesis: promotes ubiquitination of DPCs, leading to their degradation by the proteasome (By similarity). Has also been proposed to play a role in promoting translesion synthesis by mediating the assembly of 'Lys-63'-linked poly-ubiquitin chains on the Y-family polymerase POLN in order to facilitate bypass of DNA lesions and preserve genomic integrity (PubMed:24553286). The function in translesion synthesis is however controversial (PubMed:26595769). Acts as a regulator of the spindle assembly checkpoint (PubMed:25335891). Also acts as a negative regulator of innate immune signaling by inhibiting activation of NF-kappa-B mediated by TNF (PubMed:22945920). Negatively regulates TLR3/4- and RIG-I-mediated IRF3 activation and subsequent IFNB1 production and cellular antiviral response by promoting 'Lys-48'-linked polyubiquitination of TNK1 leading to its proteasomal degradation (PubMed:22945920)

The "TRAIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets